Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Kelly, W.; Danila, D.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P.; Armstrong, A. J.; Pook, D.; Kim, M.; Dorff, T.; Fischer, S.; Lin, Y. C.; Horvath, L. G.; Sumey, C.; Yang, Z.; Jurida, G.; Connarn, J.; Penny, H.; Stieglmaier, J.; Appleman, L. J. |
| Abstract Title: | Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S953 |
| End Page: | S954 |
| Language: | English |
| ACCESSION: | WOS:001087480202435 |
| DOI: | 10.1016/j.annonc.2023.09.2715 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1765O -- Source: Wos |
